Eco Animal Health Regulatory Approval

 
TIDMEAH 
 
 

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES BRAZILIAN MARKETING AUTHORISATION FOR AIVLOSIN® WATER SOLUBLE GRANULES FOR SWINE

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health do Brasil, has received a marketing authorisation from the Brazilian Ministry of Agriculture, Livestock and Supply (MAPA) for the use of Aivlosin® 625 mg/g water soluble granules in swine.

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

This formulation of Aivlosin® will be marketed for the treatment of ileitis (porcine proliferative enteropathy (PPE)), an enteric disease of swine. Aivlosin® water soluble granules dissolve readily in water providing a simple solution for the accurate and simultaneous treatment of large numbers of animals. Importantly, with global concerns about the use of antibiotics in production animals, this new treatment with its low therapeutic dose rate and short treatment duration meets antimicrobial stewardship guidelines.

Peter Lawrence, Chairman of ECO, commented "This approval from the Brazilian MAPA is very important in the development of Aivlosin® for swine globally. Brazil is one of the world's leading producers and exporters of pork and this new formulation will enhance our ability to offer an expanded range of valuable therapeutic tools to swine producers for both the domestic and export markets ".

Contacts:

ECO Animal Health Group plc

 
Peter Lawrence                              020 8336 6190 
Marc Loomes                                 020 8447 6906 
Spiro Financial 
Anthony Spiro                               020 8336 6196 
Peel Hunt LLP (Nominated Adviser) 
Dan Webster, Richard Brown, George Sellar   020 7418 8900 
N+1 Singer (Joint Broker)                   020 7496 3000 
Mark Taylor, Brough Ransom 
 
 

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161204005014/en/

 
This information is provided by Business Wire 
 
 

(END) Dow Jones Newswires

December 05, 2016 02:00 ET (07:00 GMT)